Kami J. Maddocks

9.8k citations

197 papers · 3.7k indexed · 2 hit papers · h-index 30

Impact in

Genetics top 0.2%
- Chronic Lymphocytic Leukemia Research
Pathology and Forensic Medicine top 0.5%
- Lymphoma Diagnosis and Treatment

Papers in

Genetics 148
- Chronic Lymphocytic Leukemia Research 148
Pathology and Forensic Medicine 140
- Lymphoma Diagnosis and Treatment 139

Co-authors: John C. Byrd Jeffrey A. Jones Joseph M. Flynn Amy J. Johnson Leslie A. Andritsos Kristie A. Blum Jennifer A. Woyach Farrukh T. Awan
Journals: Blood (74 papers)Journal of Clinical Oncology (29 papers)Hematological Oncology (12 papers)Leukemia (6 papers)Blood Advances (6 papers)
Partner nations: United States Poland Italy

In The Last Decade

Kami J. Maddocks

184 papers receiving 3.6k citations

Hit Papers

align trajectories log scale

Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study 2020 · 324 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2020 The Lancet Oncology
2017 Journal of Clinical Investigation

Peers

Countries citing papers authored by Kami J. Maddocks

Since Specialization

Citations

This map shows the geographic impact of Kami J. Maddocks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kami J. Maddocks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kami J. Maddocks more than expected).

Fields of papers citing papers by Kami J. Maddocks

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kami J. Maddocks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kami J. Maddocks. The network helps show where Kami J. Maddocks may publish in the future.

Co-authors

The 25 scholars most cited alongside Kami J. Maddocks, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Kami J. Maddocks Line = papers co-authored together Kami J. Maddocks links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Secondary myeloid malignancy after CAR T cell therapy for non-Hodgkin lymphoma (NHL). Journal of Clinical Oncology ·Alma Habib, Rina Li Welkie, Jacob Butman, Pedro C. Silberman, José Vicente Forero-Forero, Yazeed Sawalha, Beth Christian, Kami J. Maddocks, Narendranath Epperla, Samantha Jaglowski, David A. Bond, Hannah Choe, Jonathan E. Brammer, Adam S. Kittai, Evandro D. Bezerra, Timothy Voorhees, Sumithira Vasu, Sarah Wall, Marcos J.G. De Lima, Nathan Denlinger	2024	2
2	MRD-Driven Time-Limited Therapy of Acalabrutinib and Lenalidomide Plus Rituximab (ALR) or Obinutuzumab (ALO) in Patients with Treatment-Naïve Mantle Cell Lymphoma: Phase 2 Trial Outcomes with MRD and cfDNA Analyses Blood ·Jia Ruan, David A. Bond, Bijal Shah, John N. Allan, Sarah C. Rutherford, Caitlin Gribbin, Zhengming Chen, Brittany Hobbie, Melinda Harbhajan, T. Sahni, Wayne Tam, Bhavneet Bhinder, Michael Sigouros, Giorgio Inghirami, Selina Chen‐Kiang, Olivier Elemento, Kami J. Maddocks, John P. Leonard, Peter Martin	2024	2
3	CT-166 Long-Term Safety With ≥12 Months of Pirtobrutinib in Relapsed/Refractory B-Cell Malignancies Clinical Lymphoma Myeloma & Leukemia ·Catherine E. Muehlenbein, Catherine C. Coombs, Nirav N. Shah, Wojciech Jurczak, Jennifer A. Woyach, Chan Y. Cheah, Krish Patel, Kami J. Maddocks, Yucai Wang, Chunxiao Wang, Sarang Abhyankar, Donald E. Tsai, Toby A. Eyre	2023	1
4	Zanubrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results from a Phase 1b Clinical Trial Blood ·Yazeed Sawalha, Rina Li Welkie, Anna Krivenko, Brian Hess, Audrey M. Sigmund, Timothy Voorhees, Walter Hanel, David A. Bond, John Reneau, Narendranath Epperla, Lapo Alinari, Jonathan E. Brammer, Beth Christian, Robert A. Baiocchi, Kami J. Maddocks	2023	0
5	P1087: PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS AND SUBGROUP ANALYSIS FROM THE PHASE 1/2 BRUIN STUDY WITH >3 YEARS FOLLOW-UP FROM START OF ENROLLMENT HemaSphere ·Wojciech Jurczak, Pier Luigi Zinzani, Toby A. Eyre, Chan Y. Cheah, Chaitra S. Ujjani, Koji Izutsu, Shuo Ma, Ian W. Flinn, Alvaro J. Alencar, David Lewis, Krish Patel, Kami J. Maddocks, Yucai Wang, Talha Munir, Andrew D. Zelenetz, Minna Balbas, Donald E. Tsai, Chunxiao Wang, Michael Wang, Nirav N. Shah	2023	1
6	Pirtobrutinib in covalent BTK-inhibitor (cBTKi) pre-treated mantle cell lymphoma (MCL): Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment. Journal of Clinical Oncology ·Nirav N. Shah, Wojciech Jurczak, Pier Luigi Zinzani, Toby A. Eyre, Chan Y. Cheah, Chaitra S. Ujjani, Koji Izutsu, Shuo Ma, Ian W. Flinn, Alvaro J. Alencar, David Lewis, Krish Patel, Kami J. Maddocks, Yucai Wang, Talha Munir, Andrew D. Zelenetz, Minna Balbas, Donald E. Tsai, Chunxiao Wang, Michael Wang	2023	1
7	Five‐year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the Phase II L‐MIND study Hematological Oncology ·Johannes Duell, Pau Abrisqueta, Marc André, Marinela Augustin, Gianluca Gaïdano, (unknown), Wojciech Jurczak, Nagesh Kalakonda, Anna Marina Liberati, Kami J. Maddocks, Tobias Menne, Zsolt Nagy, Olivier Tournilhac, Abhishek Bakuli, Aasim Amin, Konstantin Gurbanov, Gilles Salles	2023	1
8	Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents Cancer Medicine ·Muhammad Salman Faisal, Walter Hanel, Timothy Voorhees, Rui Li, Ying Huang, Abdullah Khan, David A. Bond, Yazeed Sawalha, John Reneau, Lapo Alinari, Robert A. Baiocchi, Beth Christian, Kami J. Maddocks, Yvonne A. Efebera, Sam Penza, Ayman Saad, Jonathan E. Brammer, Marcos de Lima, Samantha Jaglowski, Narendranath Epperla	2023	2
9	Clinical Treatment Guidelines for Tafasitamab plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma The Oncologist ·Adrienne Nedved, Kami J. Maddocks, Grzegorz S. Nowakowski	2023	4
10	PIRTOBRUTINIB IN COVALENT BTK‐INHIBITOR PRE‐TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS, SUBGROUP ANALYSIS FROM BRUIN WITH >3 YEARS FOLLOW‐UP FROM START OF ENROLLMENT Hematological Oncology ·Chan Y. Cheah, Nirav N. Shah, Wojciech Jurczak, Pier Luigi Zinzani, Toby A. Eyre, Chaitra S. Ujjani, Koji Izutsu, Shuo Ma, Ian W. Flinn, Alvaro J. Alencar, David Lewis, Krish Patel, Kami J. Maddocks, Y. Wang, T Munir, Andrew D. Zelenetz, Minna Balbas, Donald E. Tsai, C. Wang, M. L. Wang	2023	0
11	Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma Blood ·Jeffrey P. Ward, Melissa M. Berrien-Elliott, Felicia Gomez, Jingqin Luo, Michelle Becker‐Hapak, Amanda F. Cashen, Nina D. Wagner‐Johnston, Kami J. Maddocks, Matthew Mosior, Mark P. Foster, Kilannin Krysiak, Alina Schmidt, Zachary L. Skidmore, Sweta Desai, Marcus P. Watkins, Anne Fischer, Malachi Griffith, Obi L. Griffith, Todd A. Fehniger, Nancy L. Bartlett	2021	23
12	Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Hodgkin Lymphoma Blood ·Alex F. Herrera, Carmelo Carlo‐Stella, Graham P. Collins, Kami J. Maddocks, Nancy L. Bartlett, Kerry J. Savage, Paolo F. Caimi, Brian Hess, Pier Luigi Zinzani, Hans G. Cruz, Luqiang Wang, Jay Feingold, Jens Wuerthner, Stephen M. Ansell	2020	14
13	Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study The Lancet Oncology ·Gilles Salles, Johannes Duell, Eva González‐Barca, Olivier Tournilhac, Wojciech Jurczak, Anna Marina Liberati, Zsolt Nagy, Aleš Obr, Gianluca Gaïdano, Marc André, Nagesh Kalakonda, Martin Dreyling, Johannes Weirather, Maren Dirnberger‐Hertweck, Sumeet Ambarkhane, Günter Fingerle‐Rowson, Kami J. Maddocks Hit paper breakdown →	2020	324
14	Second cancer incidence in CLL patients receiving BTK inhibitors Leukemia ·David A. Bond, Ying Huang, James L. Fisher, Amy S. Ruppert, Dwight H. Owen, Erin M. Bertino, Kerry A. Rogers, Seema A. Bhat, Michael R. Grever, Samantha Jaglowski, Kami J. Maddocks, John C. Byrd, Jennifer A. Woyach	2020	33
15	Modulation of immune checkpoint molecule expression in mantle cell lymphoma Leukemia & lymphoma ·Bonnie K. Harrington, Esther F. Wheeler, Kasey Hornbuckle, Arwa Y. Shana’ah, Youssef Youssef, Lisa Smith, Quais N. Hassan, Brett Klamer, Xiaoli Zhang, Meixiao Long, Robert A. Baiocchi, Kami J. Maddocks, Amy J. Johnson, John C. Byrd, Lapo Alinari	2019	23
16	Initial Results of the Phase 2 Treatment Naive Cohort in a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia Blood ·Kerry A. Rogers, Ying Huang, Amy Stark, Farrukh T. Awan, Kami J. Maddocks, Jennifer A. Woyach, Thomas Whitlow, John C. Byrd, Jeffrey A. Jones	2017	17
17	The relation of illness perceptions to stress, depression, and fatigue in patients with chronic lymphocytic leukaemia Psychology and Health ·Travis D. Westbrook, Kami J. Maddocks, Barbara L. Andersen	2016	20
18	Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma Leukemia & lymphoma ·Farrukh T. Awan, Joseph M. Flynn, Jeffrey A. Jones, Leslie A. Andritsos, Kami J. Maddocks, Ellen J. Sass, Margaret S. Lucas, Weihong Chase, Sharon Waymer, Yonghua Ling, Yao Jiang, Mitch A. Phelps, John C. Byrd, David Lucas, Jennifer A. Woyach	2015	12
19	Auranofin Induces Lethal Oxidative and Endoplasmic Reticulum Stress and Exerts Potent Preclinical Activity against Chronic Lymphocytic Leukemia Cancer Research ·Warren Fiskus, Nakhle S. Saba, Min Shen, Mondana Ghias, Jinyun Liu, Soumyasri Das Gupta, Lata Chauhan, Rekha Rao, Sumedha Gunewardena, Kevin Schorno, Christopher P. Austin, Kami J. Maddocks, John C. Byrd, Ari Melnick, Peng Huang, Adrian Wiestner, Kapil N. Bhalla	2014	198
20	Identification of endoplasmic reticulum stress-inducing agents by antagonizing autophagy: a new potential strategy for identification of anti-cancer therapeutics in B-cell malignancies Leukemia & lymphoma ·Emilia Mahoney, Kami J. Maddocks, Joseph M. Flynn, Jeffrey A. Jones, Sara L. Cole, Xiaoli Zhang, John C. Byrd, Amy J. Wagoner Johnson	2013	22

About Kami J. Maddocks

Kami J. Maddocks is a scholar working on Genetics, Pathology and Forensic Medicine, Hematology, Oncology and Gastroenterology, having authored 197 papers that have together received 3.7k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (148 papers), Lymphoma Diagnosis and Treatment (139 papers), CAR-T cell therapy research (33 papers), Chronic Myeloid Leukemia Treatments (25 papers), Monoclonal and Polyclonal Antibodies Research (21 papers), Viral-associated cancers and disorders (16 papers), Acute Lymphoblastic Leukemia research (16 papers) and Advanced Breast Cancer Therapies (15 papers). The work is most often cited by research in Genetics (1.8k citations), Pathology and Forensic Medicine (2.1k citations), Oncology (1.5k citations), Hematology (479 citations) and Immunology (893 citations). Kami J. Maddocks has collaborated with scholars based in United States, Poland and Italy. Frequent co-authors include John C. Byrd, Jeffrey A. Jones, Joseph M. Flynn, Amy J. Johnson, Leslie A. Andritsos, Kristie A. Blum, Jennifer A. Woyach, Farrukh T. Awan, Samantha Jaglowski and Gerard Lozanski. Their work appears in journals such as Blood, Journal of Clinical Oncology, Hematological Oncology, Leukemia and Blood Advances.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact